Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGC028 in Advanced Solid Tumors
NCT06723236Phase 1Recruiting
- Sponsor
- MacroGenics
- Start
- Feb 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of mgc028 in solid tumor, non-small cell lung cancer (NSCLC), cholangiocarcinoma (CCA) and 2 more (9 cohorts), sponsored by MacroGenics. Primary endpoint: Number and Types of Adverse Events up to 25 months. Started Feb 2025; status: recruiting.
02
Drugs
mgc028
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)cholangiocarcinoma (CCA)pancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06723236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723236.